Adjuvant Sertraline Treallnent for Chronic Schizophrenia :A Randomized, Double Blind, Placeho-Controlled Study.
- Author:
Min Soo LEE
;
Yong Ku KIM
;
Sang Kyu LEE
;
Kwang Yoon SUH
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Chronic schizophrenia;
Double-blind;
Sertaline;
Haloperidol
- MeSH:
Haloperidol;
Hospitalization;
Humans;
Inpatients;
Schizophrenia*;
Sertraline*
- From:Journal of the Korean Society of Biological Psychiatry
1997;4(1):127-131
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study. METHOD: Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen, Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6 and 8 weeks of treatment. RESULTS: The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI and S-A scale scores at any between sertraline and placebo treatment. CONCLUSION: This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.
